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Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. It is often associated with an
increased efflux of a variety of structurally unrelated anticancer drugs by ATP-binding cassette (ABC) transporters
including P-gp, ABCG2 and MRP1. MicroRNAs (miRNAs) are small non-coding RNAs that govern posttranscriptional
regulation of target genes by interacting with specific sequences in their 3′ untranslated region (3′UTR), thereby
promoting mRNA degradation or suppressing translation. Accumulating evidence suggests that alterations in
miRNAs contribute to resistance to anticancer drugs. While miRNAs are well-known to be dysregulated in cancer,
recent literature revealed that miRNA levels in biological samples may be correlated with chemotherapy response. This
review summarized the coordinated network by which miRNA regulated MDR transporters. The usefulness of miRNAs
as prognostic biomarkers for predicting chemotherapeutic outcome is discussed. MiRNAs may also represent druggable
targets for circumvention of MDR.
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Resistance to anticancer drugs remains a major unre-
solved obstacle to successful chemotherapy. It has been
estimated that most cancer deaths, if not all, are caused
by chemotherapy failure because tumors quickly develop
resistance after exposure to drugs [1]. In order to de-
velop novel strategies to combat cancer drug resistance
and to improve patient survival, a thorough under-
standing of its mechanisms is therefore badly needed.
The causes of cancer drug resistance are multifactorial,
including decreased accumulation/increased dispos-
ition of anticancer drugs, mutation of drug targets, en-
hanced cell repair and altered cell death pathways.
However, the most common and extensively studied
mechanism is the overexpression of the energy-dependent
ATP-binding cassette (ABC) drug efflux transporters
such as P-glycoprotein (MDR-1/P-gp/ABCB1), multidrugCorrespondence: kennethto@cuhk.edu.hk
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stated.resistance related protein (MRP-1/ABCC1), and breast
cancer resistance protein (BCRP/MXR/ABCP/ABCG2)
[2]. It is associated with an increased efflux of cyto-
toxic drugs, causing multidrug resistance (MDR) be-
cause cytotoxic drugs from different chemical structures
are affected simultaneously.
MicroRNAs (miRNAs) are short endogenous non-
coding RNAs that repress gene expression in a variety of
eukaryotic organisms. Gene regulation by miRNAs is
mediated by the formation of imperfect hybrids with the
3′untranslated region (3′UTR) sequences of the target
mRNAs, leading to mRNA degradation and/or transla-
tional inhibition [3]. They play important roles in several
cellular processes, such as proliferation, differentiation,
apoptosis, and development, by simultaneously control-
ling the expression level of hundreds of genes. MiRNAs
are predicted to regulate the expression of up to one
third of human protein-coding genes [4-6].
Numerous recent studies have shown that miRNA ex-
pression profiles differ between normal tissues and can-
cerous cells derived from the same organ, and alsos an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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http://www.jbiomedsci.com/content/20/1/99between cancer types [7]. MiRNAs can act as oncogenes
or tumor suppressors, contributing to different pathways
in tumorigenesis [8,9]. They may be used for diagnostic
and prognostic purposes and they also constitute novel
targets for cancer treatment [10,11]. Recently, the evi-
dence for the roles of miRNAs in determining drug
sensitivity/resistance has been emerging. This review
summarized the current understanding about the role
of miRNAs in mediating cancer drug resistance. More
emphasis is placed on miRNA-related regulation of the
MDR transporters, though other mechanisms causing
drug resistance not related to transporters will also be
discussed. The possible application of miRNA-transporters
regulatory network for predicting chemotherapeutic re-
sponse will be highlighted. Novel strategies aiming to target
miRNA-related pathways for the circumvention of multi-
drug resistance will also be elaborated.
Review
Aberrant expression of miRNAs and cancer drug
resistance
Evidence pointing to the role of miRNAs in determining
drug sensitivity and MDR is emerging. MiRNA expres-
sion is largely dysregulated in drug-resistant cancer cells
[12,13]. In a recent study on a doxorubicin-resistant
breast cancer cell line MCF-7/DOX, a profound dysreg-
ulation of the miRNA profile and altered expression of
two important miRNA processing enzymes Dicer and
Argonaute 2 was reported [14]. The remarkable correl-
ation between specific miRNA expression and the corre-
sponding changes in protein levels of their specific
targets having well-documented role in cancer drug re-
sistance, may thus implies a mechanistic link between
miRNAome dysregulation and the MDR phenotype.
Moreover, miRNA expression patterns in the NCI-60
drug screen cell lines are significantly correlated to the
sensitivity patterns of the cancer cells for a variety of
anticancer drugs [15]. Furthermore, numerous miR-
NAs have been found to regulate drug resistance genes
such as ABCG2 [16-18], BCL2 [19], DHFR [20], MDR1
[14] and PTEN [21]. Importantly, modulation of miRNA
expression or function can alter sensitivity of cancer cells
to anticancer drugs. This could be achieved by inhibiting
the function of up-regulated miRNAs or restoring the ex-
pression of down-regulated miRNAs. Together, miRNAs
may represent key players in both intrinsic and acquired
MDR in cancer cells [22].
The cause of cancer drug resistance is multifactorial. The
role of miRNAs in mediating cancer drug resistance is sep-
arately discussed below according to whether they are
regulating to (I) MDR transporters-mediated (Table 1); or
(II) non-MDR transporters-mediated mechanisms (Table 2).
The list is by no means exhaustive. We aim to illustrate the
representative ones with potentially wider implications.Regulation of ABC transporters-mediated MDR by
miRNAs
Direct regulation by miRNAs
ABCG2 (also known as BCRP/MXR/ABCP)
ABCG2 is the first MDR transporter reported to be regu-
lated by miRNA-mediated mechanism. It is one of the
major ABC transporters contributing to the MDR pheno-
type. Overexpression of the ABCG2 gene is frequently ob-
served in cancer cell lines selected with chemotherapeutic
drugs [2,45]. To date, most studies examining the regula-
tion of ABCG2 have focused on transcription. Gene
amplification, chromosome translocation, and the use
of alternative 5′ promoters due to differential expression
of splice variants at the 5′-untranslated region (5′UTR) of
ABCG2 mRNA have been reported to play important
roles in the increased expression of ABCG2 [46,47]. In
contrast, the understanding about posttranscriptional
regulation of ABCG2 has just started to evolve.
To date, a few miRNAs (miR-520 h [36,37], -519c
[16,17], -328 [18], -181a [38], & -487a [39]) have been
identified by different research groups independently to
regulate ABCG2 expression by interacting directly with
ABCG2 3′UTR and to determine the sensitivity of can-
cer cells to chemotherapeutic drugs (Table 1). Consistent
with the hypothesis that aberrant miRNA expression can
cause cancer drug resistance, low miR-328 expression
was found to correlate with the overexpression of ABCG2
in resistant MCF-7/MX100 breast cancer cells [18]. In a
human retinoblastoma cell line model, it has been further
demonstrated that low expressions of all three miRNAs
(miR-328, -519c, & -520 h) correlate very well with high
ABCG2 expression, with concomitant expression of other
stem cell markers including CD133 and ALDH1A1 [35].
On the other hand, miR-520 h has been reported to pro-
mote differentiation of hematopoietic stem cells by
inhibiting ABCG2 expression [36]. ABCG2 has been
suggested to be a survival factor for stem or cancer
stem cells (CSCs) [48]. Thus these findings collectively
support an important role played by miRNAs in main-
taining high ABCG2 level in CSCs, leading to drug re-
sistance. It will be interesting to verify if the same
phenomenon is also observed in tumor samples from
patients not responding to cancer chemotherapy.
Drug-resistant cancer cells escape miR-519c-mediated
ABCG2 repression by shortening of ABCG2 mRNA 3′
UTR An additional layer of complexity in miR-519c-
mediated regulation of ABCG2 has been proposed,
which is associated with alternative cleavage and poly-
adenylation of the 3′UTR of ABCG2 mRNA, to facili-
tate the drug resistance phenotype [17]. ABCG2 mRNA
was found to be more stable in drug-selected and
ABCG2-overexpressing resistant cell lines than in their
parental counterparts [16,17]. Given that the expression





Direct binding site(s) on target gene? Prediction by miRNA
database(s)




ABCB1 miR-27a↑ Indirect regulation-targets HIPK2 (a transcriptional
corepressor that inhibits HIF-1αactivity), thereby
indirectly activating MDR-1/P-gp
TargetScan suggests
that HIPK2 is a possible
target for miR-27a
Serendipitous testing of miR-27a
in the development of drug
resistance in ovarian cancer
cell lines
Ovarian No [23]
miR-27a↑, miR-451↑ Likely indirect regulation – miRNA microarray profiling Ovarian No [24]
(i.e. not via ABCB1 3′UTR)
miR-27a & miR-451 mimics elevate ABCB1
mRNA
miR-122↓ NO attempt to verify binding of miR-122 on
MDR-1 3′UTR
NOT performed Serendipitous testing of
downregulation of MDR
related genes (MDR-1,








(i.e. not via ABCB1 3′UTR)
- antagomir of miR-296 decrease ABCB1
promoter activity
miR-298↓ Confirmed by luciferase reporter assay / MDR-1
3′UTR miRNA site deletion / miRNA mimic /
miRNA inhibitor
miRanda miRNA microarray Breast cancer No [27]
miR-1253↓
let-7 g↓ Indirect regulation Ovarian Yes [28]
• targets IMP-1 (a RNA-binding protein)
• IMP-1 is known to stabilize MDR1 mRNA
• loss of let-7 g commonly observed in various
cancers could therefore allow overexpression of
IMP-1 and stability of MDR-1/P-gp to mediate
drug resistance
ABCC1 miR-326↓ Confirmed by luciferase reporter assay / ABCC1
3′UTR miRNA site deletion / gene expression
analysis after transfection with miR-326
mimic









Serendipitous study of the role of




ABCC2 miR-297↓ Luciferase reporter/miRNA mimic/miRNA
inhibitor
TargetScan miRNA microarray profiling Colorectal Yes [31]
ABCC3 &
ABCC6
miR-9*↓ Indirect regulation – PicTar, TargetScan,
miRBase, miRanda
Serendipitous study of the role of
ID4 in chemoresistance of induced
glioma stem cells
Glioma Yes [32]
















Table 1 miRNAs reported to regulate MDR transporters to mediate chemoresistance (Continued)
• novel ID4-miR-9*-SOX2-ABCC3/ABCC6
regulatory pathway
• ID4 was found to confer chemoresistance
to glioma stem cells by inducing the
expression of two SOX2-mediated ABC
transporters (ABCC3 & ABCC6) through
suppression of miR-9*
ABCG2 miR-212↓, miR-328↓ Effect of miR-212 & miR-328 on ABCG2
expression was evaluated by gene expression
analysis and luciferase reporter gene assay






miR-328↓ Confirmed by luciferase reporter assay /
ABCG2 3′UTR miRNA site deletion / miRNA
mimic / miRNA antagomir
PITA; TargetScan Bioinformatic analysis Breast No [18]
miR-328↓ Confirmed by luciferase reporter assay /
gene expression analysis after transfection
with miRNA mimic or inhibitor
– miRNA microarray analysis on






Confirmed by luciferase reporter assay with
site-directed gene mutagenesis / gene









of ABCG2 3′UTR escape
miR-519c repression)
Confirmed by luciferase reporter assay with
site-directed gene mutagensis on ABCG2
3′UTR miRNA site / gene expression analysis





Bioinformatic analysis Colon No [16,17]
miR-520 h↓ Confirmed by luciferase reporter assay +/-
miRNA mimic & inhibitor
PicTar, miRanda,
TargetScan
miRNA microarray profiling of
CD34+ hematopoietic cells
Leukemia No [36]




Bioinformatic analysis Pancreatic No [37]
miR-181a↓ Confirmed by luciferase reporter assay and
gene expression analysis +/- miRNA mimic
& inhibitor
RNAhybrid miRNA microarray analysis to
compare sensitive and resistant
cells
Breast No [38]
miR-487a↓ Confirmed by luciferase reporter assay and
gene expression analysis +/- miRNA mimic
& inhibitor Confirmed by luciferase reporter




Bioinformatic analysis Breast No [39]

























Identification method Cancer type/Significance/Specific





BAX Pro-apoptotic miR-296↑ Luciferase reporter
assay +miRNA
antagomir
– miRNA microarray profiling Esophageal squamous cell carcinoma Yes [26]




miRBase & TargetScan miRNA microarray profiling Gastric No [19]
miR-16↓









miRNA microarray profiling Colorectal No [40]
BCL2 &
SIRT1
Anti-apoptotic miR-34a↓ Direct miRNA effect




TargetScan Mechanistic investigation of
miR-34a/Bcl-2 and miR-34a/
SIRT1 pathways in taxane-
based chemotherapy











– miRNA microarray analysis Melanoma /miR-200c is commonly found
to be downregulated in malignant melanoma
that possess self-renewal cancer stem-cell like
property and are more invasive. The prominent
miR-200c downregulation is accompanied by
Bmi-1 overexpression, which was found to
cause loss of E-cadherin (thereby EMT) and
overexpression of MDR transporters (including
ABCG2, ABCG5 and MDR).
Yes [42]
CDH1 EMTb transition mR-200c↓ Indirect regulation:
The two miRNAs
repress ZEB1 & ZEB2,
thereby leading to loss
of E-cadherin and a
EMT phenotype
– Mechanistic investigation of
the role of miRNAs in EMT-
linked docetaxel resistance in
prostate cancer
Prostate/Docetaxel resistance/Docetaxel
treatment triggers EMT to inhibit apoptosis















MiRanda & miRBase A 829C > T SNP identified in
DHFR gene in Japanese
population was found to be
associated with increased
DHFR message
Fibrosarcoma/methotrexate resistance No [20]
HIPK2 Tumor
suppressor
miR-27a↑ NO attempt to verify
binding of miR-27a on
HIPK2 3′UTR
TargetScan Identified during the study of































– miRNA microarray profiling Resistance to microtubule –binding
chemotherapeutic drugs
No [44]
a PcG = polycomb group protein (transcriptional repressor).
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http://www.jbiomedsci.com/content/20/1/99level of miR-519c in the parental and resistant cells does
not differ too much in the cell line model studied, the in-
crease in mRNA stability was subsequently tied to a miss-
ing miR-519c binding site in the truncated 3′UTR of
ABCG2 mRNA in drug resistant cells [17]. MiR-519c can-
not bind to ABCG2 mRNA in the resistant cells because
of the shorter 3′UTR, and thus miRNA-mediated mRNA
degradation and/or protein translation block are relieved,
contributing to ABCG2 overexpression (Figure 1).
In eukaryotes, polyadenylation is an important process
that produces mature mRNA for translation. A poly(A)
tail is added to 3′ end of mRNA at the end of transcrip-
tion, which protects the mRNA molecule from enzym-
atic degradation in the cytoplasm, aids in transcription
termination, export of the mRNA from nucleus, and
translation [49]. Importantly, alternative polyadenylation
can occur when several polyA signals lie in the last exon
of a protein-coding gene, generating mRNA isoforms
with different 3′UTR length. While the phenomenon of
alternative cleavage and polyadenylation has been known
for decades, it has only been fully appreciated recently
[50]. The majority of human genes contain at least two
polyA sites [51], and alternative cleavage and polyadeny-
lation has been shown to be fairly common in multiple
organisms [50]. In general, proliferative cells, such as in-
duced pluripotent stem cells and cancer cells, show a
global shortening of 3′UTR as compared with their less
proliferative counterparts [52-55]. As gene regulation
mechanisms mediated at the 3′UTRs are mostly repres-
sive, it is generally assumed that a truncated 3′UTR will
result in higher mRNA and/or protein levels [50]. It has













Figure 1 A proposed model for ABCG2 regulation by miR-519c. ABCG
cells but only the shorter forms in drug-resistant S1M1-80 cancer cell line [
in parental cells, thus allowing ABCG2 in resistant cells to escape from theimRNAs in cancer cells leads to increased protein abun-
dance [54,56]. Intriguingly, the truncation of the ABCG2
3′UTR has also been reported in an undifferentiated hu-
man embryonic stem (HuES) cell line where its high
ABCG2 expression was associated with the short 3′UTR
variant forms [57]. In contrast, another differentiated
HuES cell line with lower ABCG2 levels possesses a
longer 3′UTR variant [57]. Sandberg et al. also found
that rapidly proliferating cells express ABCG2 mRNA
with shorter 3′UTRs, presumably to escape miRNA
regulation [52].
ABCB1 (MDR-1/P-gp)
ABCB1 (MDR-1/P-gp) is the most extensively studied
MDR transporter, which was discovered more than
30 years ago [58]. Overexpression of MDR-1/P-gp con-
fers cancer cells resistance to a broad range of structur-
ally and functionally diverse chemotherapeutic drugs
[59]. It was proposed to express in more than 50% of all
drug-resistant human tumors. Not long after the identi-
fication of the miRNAs regulating ABCG2, a few miR-
NAs directly repressing ABCB1 through binding to its
3′UTR (miR-27a, -451, -296, -298, -338, -1253) have
been reported (Table 1; [14,26,27]). Downregulation of
these miRNAs in resistant cancer cells leads to drug
resistance.
ABCC1 (MRP-1)
Multidrug resistance-associated protein (ABCC1/MRP-1)
transports a wide range of different drug classes and is also
known to play a critical role in the development of MDR







2 mRNA adopts predominantly a long form of 3′UTR in parental S1
16,17]. MiR-519c (and miR-328) can only bind to the long ABCG2 3′UTR
r repression and thereby acquiring a higher expression.
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date, only miR-326 [29] and miR-1291 [30] were reported
to modulate MRP-1 expression directly via interacting
with its 3′UTR. In VP-16-selected MRP-1-overexpressing
MCF-7 resistant cells, miR-326 was found to be downreg-
ulated and lead to MRP-1 overexpression. MiR-1291 has
just been recently reported to mediate doxorubicin resist-
ance in pancreatic cancer cells by targeting ABCC1 [30].
It was derived from a small nucleolar RNA (snoRNA:
miR-1291/SNORA34), a new class of non-coding regula-
tory RNAs that is known to control the posttranscrip-
tional modification of ribosomal RNAs [30]. The tissue or
cell type specific processing of SNORA34 to miR-1291,
and thus the overexpression of miR-1291, in pancreatic
cancer may allow the development of tumor targeting
therapy to combat MDR by selectively intervening the
miR-1291 pathway.
ABCC2 (MRP-2)
MDR-associated protein 2 (MRP-2) is a unique ABC
transporter that can mediate platinum (Pt) drug resist-
ance [60]. Pt-based anticancer drugs, including cisplatin
and oxaliplatin, are the mainstay of treatment for most
solid tumors. ABCC2 can recognize GSH-conjugated
form of Pt drugs and effectively pump them out of the
cells to confer resistance. To date, only miR-297 has
been reported to be down-regulated in a oxaliplatin-
resistant colon cancer cell model (HCT116/L-OHP) to
cause ABCC2 overexpression and Pt drug resistance
[31]. A complementary binding site for miR-297 was
identified on ABCC2 3′UTR to mediate the specific
gene repression.
Indirect regulation by miRNAs
MDR-1/P-gp
Besides the various miRNAs discussed above that can
directly modulate MDR-1/P-gp expression by interacting
with complementary sequences at its 3′UTR, indirect
regulation of the MDR transporter has also been reported.
Let-7 g was reported to modulate acquired resistance of
ovarian cancer to taxanes via IMP-1-mediated stabilization
of MDR-1 [28]. IMP-1 is an RNA binding protein that sta-
bilizes the mRNA of a number of target genes, including
MDR-1 [61]. IMP-1 was known to be a validated target for
let-7 g [62]. It follows that the loss of let-7 g commonly ob-
served in various cancers [28] could allow the overexpres-
sion of IMP-1 and thereby stabilization of MDR-1/P-gp to
mediate anticancer drug resistance (Figure 2a; [28]). More-
over, a novel miR-27a/HIPK2/MDR1/P-gp pathway has
been proposed that lead to paclitaxel resistance in
ovarian cancer cells [23]. Homeodomain-interacting
protein kinase-2 (HIPK2) was reported to inhibit HIF-
1α, thereby suppressing MDR1 gene transcription and
sensitize cancer cells to doxorubicin-induced apoptosis[63]. Therefore, increased expression of miR-27a in re-
sistant cells leads to downregulation of HIPK2, which
indirectly allows HIF-1α-mediated stimulation of MDR-1/
P-gp and chemoresistance (Figure 2b; [23]).
Another noteworthy indirect mechanism for miRNA-
mediated upregulation of MDR-1/P-gp involved the epi-
genetic alteration (i.e. hypomethylation) of the MDR-1
promoter in resistant MCF-7/DOX cells (Figure 2c;
[64]). The loss of cytosine methylation in the MDR-1
promoter, which was shown to lead to P-gp overexpres-
sion and the resistance phenotype, was proposed to be
mediated by the increased expression of miR-22, miR-
29a, miR-132, and miR194. These miRNAs were known
to target DNA methyltransferases 3A and 3B and methyl
CpG binding protein 2, which mediate MDR-1 promoter
methylation [64-66]. Although the definitive proof for
this hypothesis is still lacking, it has far-reaching impli-
cation in the etiology of MDR. A number of other key
mediators of MDR (including ABCG2, BCL-2, PTEN,
etc) are known to be repressed by DNA methylation,
therefore aberrant increased expression of the aforemen-
tioned miRNAs in cancer cells may lead to derepression
of these mediators to cause MDR.ABCC3/ABCC6
Unlike most ABC transporters that are highly expressed
in various anatomic regions of the normal brain, ABCC3
and ABCC6 are not detectable in normal brain tissues
[67]. Surprisingly, the specific role played by these two
ABC transporters in the anticancer drug resistance of
glioma stem cells has been recently reported [32]. A
novel regulatory pathway Inhibitor of differentiation 4
(ID4)-miR-9*-SOX2-ABCC3/ABCC6 was proposed, which
induces the stemness potential of glioma stem cells and
chemoresistance (Figure 3). Of note, ABCC3 and ABCC6
are not direct targets for miR-9*. However, both of these
ABC transporters are transcriptionally regulated by SOX2,
which is elevated in glioma stem cells by ID4-mediated
suppression of miR-9*.Regulation of MDR via non-transporter-mediated
pathways by miRNAs
Alternations of several oncogenes (e.g. Bcl2, Ras, Src)
and tumor suppressor genes (e.g. p53, RB, and p16) are
closely associated with chemoresistance. However, the
involvement of miRNA in these processes has just begun
to be unraveled. A list of the most representative miR-
NAs regulating these non-transporter-mediated MDR
pathways is summarized in Table 2. The list is by no
means exhaustive but it aims to highlight a few examples
according to the biological effect of the miRNA target
gene (i.e. anti-apoptotic, drug metabolism, tumor sup-




Figure 3 miR-9* is involved in an indirect regulatory
mechanism of ABCC3 & ABCC6 to induce chemoresistance and



























Figure 2 Indirect regulatory mechanisms of MDR-1/P-gp by miRNAs. (a) let-7 g downregulation is commonly observed in various cancers. It
is known to target the RNA binding protein, IMP-1, which stabilizes MDR-1 mRNA. Therefore, let-7 g loss in resistant cells allows overexpression of
IMP-1 and stability of MDR-1/P-gp to mediate drug resistance [28]. (b) Homeodomain-interacting protein kinase-2 (HIPK2) is a known target of
miR-27a. HIPK2 has also been reported to inhibit HIF-1α. Increased expression of miR-27a in resistant cells leads to downregulation of HIPK2,
which indirectly allows HIF-1α-mediated stimulation of MDR-1/P-gp and chemoresistance [23]. (c) A hypothetical miRNAs-DNA methylation
machinery-MDR-1 promoter methylation pathway. Increased expression of these miRNAs in resistant cells represses various DNA methylation
mediators, thereby facilitating MDR-1 promoter demethylation and increasing P-gp efflux activity to mediate chemoresistance.
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Most anticancer drugs work by induction of
apoptosis. Alterations to susceptibility to apoptosis
may lead to resistance to conventional cancer
chemotherapy. BCL2 (encoding the protein known as
apoptosis regulator Bcl-2) is the most important pro-
survival or anti-apoptotic factor often overexpressed
in cancer and it is closely associated with chemother-
apy resistance in various cancers. A number of miR-
NAs (including miR-15b, -16, -34a, -296, -1915) have
been shown to modulate MDR by targeting BCL2
[19,26,40,41]. MiR-34a is of particular interest, where
both direct and indirect regulatory pathways have
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http://www.jbiomedsci.com/content/20/1/99been described (Figure 4a; [41]). MiR-34a can inhibit
proliferation of paclitaxel-resistant PC3PR cells by
directly suppressing expression of proteins involved
in cell-cycle regulation such as CDK6 and cyclin D1.
On the other hand, miR-34a has also been shown to
enhance apoptosis by indirectly reducing expression
of SIRT1 and Bcl2 via modulating HuR.
(b) Drug metabolism
Dihydrofolate reductase (DHFR) is a key enzyme in
cellular folate metabolism, which is the drug target
of a widely used anticancer drug methotrexate. A
naturally occurring SNP of DHFR (829C > T) has
been identified near the miR-24 binding site within
the 3′UTR of DHFR [20]. It interferes with miR-24
repression, thus resulting in DHFR overexpression
and methotrexate resistance.
(c) Tumor suppressor
A growing list of miRNAs has been identified to
regulate PTEN, an important tumor suppressor, by











Figure 4 miR-34a mediates paclitaxel resistance via both direct and ind
indirect mechanisms underlying miR-34a-mediated paclitaxel resistance. Direc
cells by directly suppressing the cell cycle regulators cyclin D1 and CDK6. Indir
pression of the anti-apoptotic gens (SIRT1 & BCL2) via modulating HuR [41]. (b
ance to apoptosis. Key signals that lead to EMT trigger expression of a vari
and Twist. These repressors are the intracellular mediators of EMT by bindi
hesion protein E-cadherin. After binding, they recruit histone deacetylases and o
Reduced cellular E-cadherin expression subsequently will lead to loss of cell-cell
vasive mesenchymal and drug resistance phenotype [43].214 was shown to interact with PTEN 3′UTR and
inhibit PTEN translation, thereby leading to activa-
tion of the Akt pathway and cisplatin resistance
[21]. The significance of this finding is that, once
the miRNA-mediated regulation pathway is under-
stood, apart from artificially altering the miRNA ex-
pression, the resistance phenotype can also be
overridden by modulation of the upstream or down-
stream events (such as using either small-molecule
Akt inhibitor or etopic expression of PTEN cDNA
lacking 3′UTR) [21].
(d) Epithelial-to-mesenchymal transition (EMT)
EMT is a cellular process that describes the change
of an epithelial to a motile mesenchymal phenotype.
Upon EMT, primary epithelial cancer cells acquire
increased invasive and migratory abilities, eventually
leading to metastases. Cancer cells selected for
docetaxel resistance was found to exhibit EMT-
triggered E-cadherin loss and reduced apoptosis








r resistant cells 
(b)
irect mechanisms. (a) Schematic representation of direct and
t pathway: miR-34a inhibit proliferation of paclitaxel-resistant PC3PR
ect pathway: miR-34a can enhance apoptosis by indirectly reducing ex-
) Indirect mechanism of miR-200c/-205-mediated EMT and resist-
ety of transcriptional repressors, including ZEB1, ZEB2/SIP1, Snail,
ng to E-box elements of genes, such as CDH1, that encode for the ad-
ther corepressors to facilitate transcriptional repression of E-cadherin.
adhesion and a series of other events, eventually leading to an in-
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of miR-200c & -205. MiR-200c & -205 repress the
transcriptional repressors, ZEB1/ZEB2, therefore re-
duced levels of these miRNAs allow more repression by
ZEB1/ZEB2 and thereby downregulation of E-cadherin
and EMT (Figure 4b; [43]). Another recent report by
Liu et al. shown that miR-200c downregulation is fre-
quently observed in metastatic melanoma, which is
accompanied by overexpression of its target Bmi-1
(a Polycomb group protein class of transcriptional
repressor) [42]. Upregulation of Bmi-1 was further
shown to increase a number of MDR transporter
genes (ABCG2, MDR1 and ABCG5) and to mediate
loss of E-cadherin, collectively leading to a more
resistant, malignant, and invasive EMT-like
phenotype [42].Genetic polymorphism in miRNA binding sites
and anti-cancer drug resistance
Regulation by miRNAs depends on the binding to seed
sequences in the 3′UTR of their target mRNAs, which
subsequently leads to degradation of mRNAs and/or
translation blockade. Therefore, both sequence comple-
mentarity and thermodynamics of the binding determine
the likelihood of interaction between miRNAs and their
targets. It follows that sequence variations such as single-
nucleotide polymorphisms (SNPs) in the miRNA target
site (more specifically in the seed region) could affect the
miRNA-mRNA interaction and subsequently expression
of the miRNA targets. To this end, a recent bioinformatics
study of the entire human genome revealed a relatively
high frequency of miRNA target site SNPs that disrupt
target sites or create new ones [70].
The most popular SNP occurring at miRNA target
site, related to anticancer drug resistance, is probably the
one identified by Mishra et al. on a miR-24 binding se-
quence that changed cell response to methotrexate [20].
The SNP (829C→ T) near the miR-24 binding site in
the 3′UTR of human dihydrofolate reductase (DHFR)
was found to interfere with miR-24-mediated repression,
thus resulting in DHFR overexpression and methotrex-
ate resistance. Similar to this 3′UTR polymorphism, the
phenomenon of alternative transcript polyadenylation
(leading to shortening of 3′UTR) described above for
the regulation of ABCG2 (Figure 1) [17] is another ex-
ample where miRNA-mediated gene regulation can
intersect with genetic variation to mediate anticancer
drug resistance.
In fact, the study of 3′UTR variations is emerging as a
new research avenue that holds promise for personalized
pharmacotherapy [71,72]. The idea of “miRNA-pharma-
cogenomics” has been proposed by Bertino et al. that
study the influence of genetic polymorphisms on miRNA
function as a way to predict drug behavior and toimprove drug efficacy [71]. Assessment of miRNA pro-
file and 3′UTR polymorphisms in patients may thus
allow personalized medicine [71].
Use of miRNAs as prognostic markers for
predicting chemotherapy response and/or
chemoresistance: a rapidly growing field
Along with strong evidence suggesting that miRNAs can
be employed clinically as biomarkers for cancer classifi-
cation, diagnosis, and prognosis [7,73,74], miRNAs are
also rapidly gaining popularity for predicting response to
chemotherapy.
(a) In vitro evidence from cell line studies
Blower et al. conducted one of the most systematic
studies correlating global expression of 279 miRNAs
and response to 3089 compounds in the NCI-60
drug screen cell line panel [15]. A good correlation
between miRNA expression patterns and compound
potency patterns was observed, thus strongly sug-
gesting a prominent role played by miRNAs in me-
diating chemoresistance. When combined with gene
expression and other biological data using multivari-
ate analysis, miRNA expression profiles may help
elucidate the complex mechanisms involved in che-
mosensitivity and chemoresistance.
(b) Evidence from clinical specimen analyses (miRNAs
expressed in tumors)
Recent data suggest that miRNA expression in
patient samples at baseline could predict
chemotherapy and radiotherapy response. A
summary of these miRNAs is compiled in Table 3.
A few representative ones are elaborated below.
let-7i: In epithelial ovarian cancer, let-7i expression
was reported to be significantly reduced in
chemotherapy-resistant patients with epithelial
ovarian cancer (n = 69, p = 0.003) [84]. Follow up
mechanistic investigation using both gain- and
loss-of-function analysis revealed that reduced let-
7i expression in ovarian and breast cancer cells are
linked to resistance to cisplatin chemotherapy
[84]. However, a contradictory finding about the
role of let-7i in drug resistance has also been re-
ported [13]. By modulating let-7i expression with
pre-miRNA or miRNA inhibitor transfection in
the NCI-60 panel of human cancer cell lines, let-7i
inhibition was found to enhance the sensitivity of
A549 cells to one of their investigational antican-
cer agent NSC670550 [13].
miR-21: miR-21 dysregulation has been reported
to be a predictor of tumor response in pancreatic
cancer patients to conventional cytotoxic chemo-
therapeutic agents, including gemcitabine, doce-
taxel, temozolomide and 5-fluorouracil [85,86].
Table 3 Representative miRNAs from patient tumor specimens as predictive markers for treatment outcome in cancer
therapy
Cancer type miRNA dysregulation Chemotherapeutic outcome prediction Reference
Metastatic breast cancer miR-26a ↑ - Multivariate analysis revealed that miR-26a and CDC2
(cell cycle regulator) are an optimal set of markers
associated with favorable outcome on tamoxifen
therapy, independently of traditional predictive factors
(menopausal status, ER & PgR mRNA expression)
[75]
- Mechanistic analysis showed that miR-26a repressed
EZH2 to upregulate ER, thereby enhancing sensitivity
to anti-estrogen therapy
CRC miR-181b↓ & let-7 g↓ Associated with responsiveness to 4th generation
fluoropyrimidine-based adjuvant therapy
[76]
CRC miR-215↑ - miR-215 level generally downregulated in clinical
CRC specimen
[77]
- ↑miR-215 caused chemoresistance of HCT116 to
methotrexate and tomudex
- No impact on treatment outcome from cisplatin and
doxorubicin
- High level of miR-215 was found in CRC stem cells
Metastatic CRC miR-146b-3p↑ & miR-486-5p↑ - miRNAs level found to be more abundant in patients
with mutant KRAS
[78]
- Predictive of resistance to cetuximab (EGFR targeting
monoclonal antibody)
Metastatic CRC miR-200b ↑ - In KRAS mutated tumors, ↑ miR-200b and ↓ miR-143
were associated with a good PFS in patients on cetuximab
[79]
miR-143 ↓
- In wild-type KRAS patients, miRNA expression did not
correlate with PFS in a multivariate model
GBM 5-miRNAs signature (miR-181d,
miR-518b, miR-524-5p, miR-566,
miR-1227)
- Patients who had low risk scores from the 5-miRNA
signature and received temozolomide treatment had
better survival
[80]
- Useful for identifying patients for more aggressive
therapy
Hepatocellular carcinoma miR-26↓ Lower miR-26 is associated with shorter overall survival
but a better response to interferon therapy
[81]
NSCLC miR-21 ↑ Increased miR-21 in patients not responding to
platinum-based chemotherapy
[82]
Lung cancer miR-128b LOH Predictive of clinical response and prolonged survival
following gefitinib treatment
[83]
Ovarian cancer let-7i↓ Predictive of resistance to cisplatin [84]
Pancreatic cancer miR-21↑ - Predictive of resistance to gemcitabine, docetaxel,
temozolomide and 5-fluorouracil
[85,86]
- Associated with shorter overall survival in the
metastatic and adjuvant setting
Pancreatic ductal adenocarcinoma miR-10b ↓ Lower levels of miR-10b is associated with improved
response to multimodality neoadjuvant therapy.
Likelihood of surgical resection, delayed time to
metastasis and increased survival
[87]
Abbreviations: CRC = colorectal cancer; EGFR = epidermal growth factor receptor; ER = estrogen receptor; GBM = glioblastoma multiforme; LOH = loss of
heterozygosity; NSCLC = non-small cell lung cancer; PFS = progression-free survival; PgR = progesterone receptor.
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profiling study conducted in a relatively large
cohort (n = 241) of patients with hepatocellular
carcinoma, a list of tumor-related miRNAs closely
associated with patient survival and treatment re-
sponse to interferon was identified [81]. Inparticular, patients whose tumors had low miR-26
expression had shorter overall survival but a better
response to interferon therapy than did patients
whose tumors had high expression of the miRNA.
miR-128b: In a cohort of 58 non-small-cell lung
cancer patients, miR-128b loss of heterozygosity
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clinical response and prolonged survival following
treatment with gefitinib [83]. Mechanistic investi-
gation in NSCLC cell lines using miR-128b mimics
or inhibitors confirmed that EGFR (the molecular
target of gefitinib) is specifically regulated by the
miRNA. LOH of chromosome 3p is a well-known
and early genetic abnormality in lung cancer. Since
miR-128b resides on the 3p22 locus, the aforemen-
tioned finding about the LOH of miR-128b could
provide a functional link between a common gen-
etic abnormality in lung cancer (i.e. loss of 3p22)
and the frequent overexpression of EGFR in
NSCLC patients. The clinical significance is that
miR-128b may be used as a useful prognostic
marker for selecting patient candidates to receive
and benefit the most from EGFR tyrosine kinase
inhibitors.
(c) Circulating miRNAs as non-invasive biomarkers for
predicting chemotherapy response
In recent years, circulating miRNAs, refering to the
miRNAs present in cell-free body fluids such as
plasma, serum, urine and saliva, etc, have been
exploited for use as biomarkers in various disease
states. These circulating miRNAs are bound to pro-
teins including argonaute2 [88] and high density
lipoprotein [89], or are encapsulated in exosomes
[90], which render them highly resistant to RNase
activity. Therefore, they can be reliably measured by
the highly sensitive and relatively inexpensive
method of quantitative polymerase chain reaction
(qPCR). Moreover, the ease of access, minimal inva-
siveness and the possibiliy of repeated sampling of
circulating miRNAs have also made them ideal can-
didates for use as biomarkers. Due to space limita-
tion, we have highlighted a few representative
circulating miRNAs that have been reported as use-
ful predictive biomarkers for chemotherapy re-
sponse (Table 4).
While a number of circulating miRNAs have been
identified as useful biomarkers for predicting
treatment response to chemotherapy and/or surgery,
the detailed mechanism is usually not determined. It
remains to be determined as to whether the
circulating miRNAs are actively released by
surviving cancer cells or derived from the dead
cancer cells. Interestingly, in prostate cancer, Lucotti
et al. has nicely demonstrated that cytotoxic
treatment of DU-145 prostate cancer cells by fludar-
abine enhanced the release of a list of exosomes-
associated prostate cancer secretary (PCS)-miRNAs,
with the exception of miR-485-3p, which is retained
by surviving cancer cells [97]. Follow-up mechanistic
investigation revealed that the intracellular retentionof miR-485-3p downregulate the transcriptional
repressor NF-Y, and thus allowing the overexpres-
sion of drug resistance genes (including TOP2A,
MDR1 and cyclin B2 pro-suvival genes) to mediate
resistance [97].
In summary, tumoral miRNA expression at
diagnosis may help predict the patients’ response
to chemotherapy and also provide insights about
mechanism of chemotherapy resistance. It may
also provide guidance for rational and personalized
chemotherapy selection. To this end, circulating
miRNA as a novel prognostic or predictive tool is
also rapidly gaining popularity [100,101] because
of the non-invasive nature of the detection
method. Moreover, miRNA-based profiling also
has another added advantage over conventional
mRNA-based methods. MiRNAs in formalin-fixed
tissues, blood plasma and serum are known to be
remarkably more stable than mRNAs to endogen-
ous RNase digestion [102], thereby enabling their
reliable extraction and analysis from patient
specimens.MiRNAs as druggable targets and miRNA-based
therapeutics for circumvention of anticancer drug
resistance
(a) MiRNA-based therapeutics
Since miRNA expression is often dysregulated in
cancer cells, approaches that modulate miRNA
activity could potentially produce specific
anti-cancer effect. With the advancement in
technology, modulation of endogenous miRNA
levels can now be achieved in several ways.
Oncogenic miRNAs can be targeted for
downregulation using various modified antisense
oligonucleotides (also known as antagomirs) to their
precursor or mature forms, whereas tumor
suppressive miRNAs may be directly upregulated by
using synthetic miRNA mimics (including siRNA-like
oligoribonucleotide duplex and chemically modified
oligoribonucleotide [103]) for an anti-cancer effect. In
particular, antagomirs, with 2′-O-methylation or
locked nucleic acid modifications, have drawn a lot of
attention. Successful in vivo silencing of miRNA has
been achieved by their systematic administration
through tail vein injections into mice [104,105]. On
the other hand, a few proof-of-concept studies
using artificial synthetic miRNAs have been
successfully performed to target a few oncogenes
and produce anticancer effect [106-108]. A list of
representative miRNAs as potential molecular
targets for cancer therapy is compiled in
Table 5.
Table 4 Representative circulating miRNAs reported to predict response to chemotherapy and/or surgery
Cancer type miRNA dysregulation
associated with poor
response
Sample type Significance Reference
Breast ↑ miR-125b Serum Increased in patiens not responding to
neoadjuvant chemotherapy
[91]
Breast ↑ miR-210 Plasma Lower miR-210 plasma levels are associated
with
[92]
- complete response to trastuzumab (HER-2
targeted monoclonal antibody)
- surgical removal of tumor
- lack of tumor metastasis to lymph nodes
Colorectal (CRC) ↑ miR17-3p Plasma - Elevated in both CRC tissue and plasma [93]
- Lower level detected in post-operative
plasma is associated with responsiveness
to surgery
Colorectal (CRC) ↑ miR-29a Serum - Elevated in both CRC tissue and plasma [93]
- Help differentiate CRC from gastric cancer,
inflammatory bowel disease and no tumor
controls
- Lower level detected in post-operative plasma
is associated with responsiveness to surgery
Colorectal (CRC) ↑ miR-27b, miR-148a,
miR-326
Plasma Elevated in patients with metastatic CRC not
responding to 5-fluouracil and oxaliplatin-based
chemotherapy
[94]
Lung ↑ miR-21 Plasma Increased; associated with resistance to
platinum-based chemotherapy
[95]
Non-Hodgkin’s lymphoma (NHL) ↓ miR-92a Plasma - Remarkably lower in NHL patients (< 5%) than
in healthy subjects
[96]
- The very low plasma level of miR-92a increased
in complete response phase but became lower
again in the relapse phase
Prostate ↑ Prostate cancer secretary
(PCS)-miRNAs
Plasma/serum - It is not clear whether circulating miRNAs are
actively released by live cancer cells or derived
from dead cancer cells.
[97]
- In vitro cytotoxic treatment of DU-145 cells
enhanced the release of exosomes-associated
PCS-miRNAs, with the exception of miR-485-3p,
which is retained by surviving cancer cells.
- The intracellular retention of miR-485-3p was
shown to downregulate the transcriptional
repressor NF-Y, thus allowing the overexpression
of a few drug resistance genes (including TOP2A,
MDR1, and cyclin B2 pro-survival genes)
Prostate ↑ miR-21 Serum - Increased in hormone-refractory prostate cancer [98]
- Associated with resistance to docetaxel-based
chemotherapy
Advanced renal cell carcinoma ↑ miR-192 Peripheral blood
samples
- Models predicting poor and prolonged response
to sunitinib were constructed
[99]
↑ miR-193a-3p
- Ontology analyses revealed relevance to
cancer-related pathways (angiogenesis and
apoptosis)
- miRNA expression signatures may be used to
identify patients who may benefit the most from
1st line therapy with sunitinib
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Table 5 MiRNAs as targets for cancer therapy
Cancer type miRNA target and its role in cancer Delivery system to modulate the miRNA in vivo* Reference
Breast cancer miR-34a – Tumor suppressor Cationic liposomes [109]
Glioblastoma miR-145 – Tumor suppressor Adenoviruses [110]
Glioblastoma miR-221-222 – Oncogene Adenoviruses [111]
Glioblastoma
Multiforme (GBM)
miR-9 – promote expression of P-gp
(a multidrug resistance efflux transporter)
- Mesenchymal stem cell-derived exosomes [112]
- To deliver anti-miR-9 to temozolomide-resistant
GBM to reduce P-gp expression for resistance reversal
Hepatocellular
carcinoma
miR-26 – Tumor suppressor Adenoviruses [113]
Lung cancer let-7 – Tumor suppressor Adenoviruses [114]
Lung cancer miR-34a – Tumor suppressor Cationic liposomes [115]
Lymphoma miR-155 – Oncogene Polymer-based nanoparticles [116]
Medulloblastoma miR-17 ~ 92 cluster family – Sonic
Hedgehog signaling




Pancreatic cancer miR-21 – Oncogene Lentiviruses [118]
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circumvention
Although the use of miRNAs for cancer
chemotherapy has not yet been realized in clinical
trials, it has recently been demonstrated in tissue
culture systems that miRNA-targeted therapy may
be useful in combination with conventional
chemo-radiotherapy to sensitize the cancer cells.
Table 6 summarizes a few representative
miRNA-modulatory approaches to circumvent
anticancer drug resistance. let-7 overexpression has
been shown to confer radiosensitivity in lung cancer
cell lines [123]. Inhibition of miR-21 and miR-200b
was reported to enhance the sensitivity of
cholangiocarcinomas to gemcitabine chemotherapy
[120]. MiR-21 is of particular interest, which is
overexpressed in most cancer types analyzed [124].ble 6 Novel approaches to circumvent chemoresistance by mod
ncer type miRNA targeted for
inhibition
Type of resistance circumv
cell lymphoma miR-21 – oncomiR addiction –





miR-9 – indirectly promoting




M miR-21 - Temozolomide
- Enhance apoptosis
ng cancer miR-92b Cisplatin resistance mediated
downregulation of the tumo
suppressor gene PTENA landmark study has been reported to illustrate
the phenomenon of “oncomiR addiction” in an
in vivo model of miR-21-induced pre-B-cell
lymphoma [119]. Most intriguingly, complete tumor
regression can be achieved in a few days when
miR-21 was inactivated by the antisense strategy
in vivo. Given that aberrant miR-21 expression is
known to reduce sensitivity of cancer cells to a
number of anticancer drugs including tamoxifen,
gemcitabine, doxorubicin and docetaxel [124],
inactivating miR-21 may represent a novel strategy
for cancer drug resistance circumvention. Most
recently, a novel approach to deliver functional
anti-miR-9 by mesenchymal stem cell-derived
exosomes to glioblastoma multiforme (GBM) cells
has been reported to circumvent P-gp-mediated
resistance to temozolomide [112]. Site-directedulating unique miRNAs






Transfection with miRNA-specific antisense
oligonucleotides
[120]
- Mesenchymal stem cell-derived exosomes [112]
- To deliver anti-miR-9 to temozolomide-
resistant GBM to reduce P-gp expression for
resistance reversal
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was achieved because mesenchymal stem cells are
able to migrate preferentially to the brain.
(c) Therapeutic drugs altering miRNA profile in cancer
cells
Apart from exhibiting aberrant expression of a few
miRNAs, human cancers are in fact characterized
by impaired miRNA processing and global miRNA
dysregulation [125]. It has been recently shown that
miRNA expression can be differentially altered by
xenobiotic drugs in difference human cell lines
[126]. The drugs identified are not necessarily
anticancer drugs. The practical implication is that
they could be safely administered with other
conventional anticancer drugs in an attempt to
reverse miRNA-mediated drug resistance. Along
this line of investigation, the fluoroquinolone class
of antibiotics has been shown to enhance RNA
interference and promote miRNA processing
[127,128]. This may represent a novel approach to
modulate multiple miRNAs simultaneously
or to restore the global miRNA expression
(i.e. micRNAome) to provide a cancer-specific
growth inhibitory effect. It has also been proposed
that specific class of drugs might be screened for
their effects on shifting the miRNA expression
profile of a cancer cell towards that of a normal
tissue [129]. To this end, the SM2miR database has
been established to provide a fairly comprehensive
respository about the influences of small molecules
on miRNA expression, which could promote the
futher development of miRNA-targeting
therapeutics [130]. Calin et al. has proposed
structure-based approaches (such as molecular
docking) to identify compounds that may target
specific miRNAs [131]. However, three-dimemsional
structure prediction of miRNA still remains a
challenge. There has also been attempts to identify
small molecules targeting specific miRNAs in
human cancers based on transcriptional responses
[132]. As more is discovered in this research area,
the specific modulation of miRNAs by therapeutic
drugs may become feasible in the future.
(d) Off-target effects
Each miRNA typically targets up to hundreds of
transcripts directly or indirectly, and multiple
miRNAs can target a given gene. It follows that
miRNAs are also tied to some tightly regulated gene
expression networks in normal cells. The
therapeutic outcome of a miRNA-targeted
chemotherapy or resistance reversal regimen may
thus depend on the number of miRNA targets and
the affinities for each of these targets that are
expressed in a given tumor microenvironment. Itcould be difficult to rule out the by-stander
off-target effects, if any. Moreover, an appropriate
method to deliver the effective miRNA mimic/
antagomir to the right cell type must also be
considered in order to prevent unwanted side
effects. Indeed, a fatal side effect as a result of
saturation of miRNA pathways has been reported in
an animal study [133]. It appears that these hurdles
have to be overcome before an effective
miRNA-targeted strategy can be realized for
circumvention of anticancer drug resistance in
cancer patients.Conclusions
The emerging role of miRNAs as regulators of gene ex-
pression, and their dysregulation in human cancer has
provided opportunities for their therapeutic application
in the capacity of cancer detection, diagnosis and prog-
nosis prediction. Selective targeting of some miRNAs
may be useful in enhancing chemosensitivity, and may
have future applications in modulating therapeutic re-
sponse to molecular targeted chemotherapeutics in se-
lected cancer subtypes. A better understanding about
the complex regulatory pathways that control miRNAs
function and their tumor-specific effect will be needed in
order to fully realize the promise of miRNAs in cancer diag-
nosis, chemotherapy and drug resistance circumvention.
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